TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy
Brief Summary: Primary Objective:

To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants with persistent moderate to severe eosinophilic asthma.

Secondary Objectives:

* To assess the safety and tolerability of Dupilumab administered SC qw for 12 weeks in participants with persistent moderate to severe eosinophilic asthma.
* To assess Dupilumab serum concentrations following qw SC dosing for 12 weeks in participants with persistent moderate to severe eosinophilic asthma.


Options:
A: Arm Label: Placebo (for Dupilumab); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Dupilumab), Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticasone monotherapy, Drug: Albuterol, Drug: Levalbuterol | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticasone monotherapy, Drug: Albuterol, Drug: Levalbuterol | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo (for Dupilumab); Assigned to Arm(s): Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Fluticasone/Salmeterol combination therapy; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Fluticasone monotherapy; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Levalbuterol; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab)
B: Arm Label: Non-drug interventional group; Type: OTHER; Interventions: Drug: Short Acting Beta Agonist (SABA) | Intervention Type: DRUG; Name: Short Acting Beta Agonist (SABA); Assigned to Arm(s): Non-drug interventional group
C: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Arm Mepolizumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Mepolizumab 100mg | Arm Label: Arm Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Mepolizumab 100mg, Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Mepolizumab 100mg; Assigned to Arm(s): Arm Mepolizumab 100 mg, Arm Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Electronic Medical Record Reminders and Panel Management to Improve Primary Care of Elderly Patients
Brief Summary: The investigators conducted a controlled trial to assess the effectiveness of electronic medical record (EMR) reminders, with or without a panel manager, on completion of health care proxy, osteoporosis screening, and influenza and pneumococcal vaccinations for patients age 65 or older. The investigators hypothesized that EMR reminders would improve adherence to practice guidelines and that benefits would be enhanced with the support of a panel manager.


Options:
A: Arm Label: Computerized Alerts; Type: EXPERIMENTAL; Interventions: Behavioral: Computerized alerts | Arm Label: Alerts PLUS Detailing; Type: EXPERIMENTAL; Interventions: Behavioral: Alerts Plus Detailing | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Computerized alerts; Assigned to Arm(s): Computerized Alerts | Intervention Type: BEHAVIORAL; Name: Alerts Plus Detailing; Assigned to Arm(s): Alerts PLUS Detailing
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: automated clinical alerts, Other: provider education | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: provider education | Intervention Type: OTHER; Name: automated clinical alerts; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: provider education; Assigned to Arm(s): 1, 2
C: Arm Label: EMR reminder; Type: EXPERIMENTAL; Interventions: Other: EMR Reminder | Arm Label: EMR reminder + Panel management; Type: EXPERIMENTAL; Interventions: Other: EMR Reminder + Panel management | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: EMR Reminder; Assigned to Arm(s): EMR reminder | Intervention Type: OTHER; Name: EMR Reminder + Panel management; Assigned to Arm(s): EMR reminder + Panel management
D: Arm Label: Alert Group; Type: EXPERIMENTAL; Interventions: Other: Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart; Assigned to Arm(s): Alert Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Subjects With Moderately Active Rheumatoid Arthritis Despite DMARD Therapy
Brief Summary: This study is designed to evaluate the effectiveness of adding etanercept to disease modifying anti-rheumatic drug (DMARD) therapy in patients with moderately active Rheumatoid Arthritis (RA).


Options:
A: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1
C: Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Biological: tocilizumab, Drug: methotrexate, Biological: 23-Valent Pneumococcal Polysaccharide Vaccine, Biological: Tetanus Toxoid Adsorbed Vaccine | Arm Label: Tocilizumab + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: tocilizumab, Drug: methotrexate, Biological: 23-Valent Pneumococcal Polysaccharide Vaccine, Biological: Tetanus Toxoid Adsorbed Vaccine | Intervention Type: BIOLOGICAL; Name: tocilizumab; Assigned to Arm(s): Methotrexate, Tocilizumab + Methotrexate | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Methotrexate, Tocilizumab + Methotrexate | Intervention Type: BIOLOGICAL; Name: 23-Valent Pneumococcal Polysaccharide Vaccine; Assigned to Arm(s): Methotrexate, Tocilizumab + Methotrexate | Intervention Type: BIOLOGICAL; Name: Tetanus Toxoid Adsorbed Vaccine; Assigned to Arm(s): Methotrexate, Tocilizumab + Methotrexate
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: etanercept, Drug: Placebo, Drug: DMARD Therapy | Arm Label: Etanercept; Type: EXPERIMENTAL; Interventions: Drug: etanercept, Drug: DMARD Therapy | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): Etanercept, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: DMARD Therapy; Assigned to Arm(s): Etanercept, Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Subjects With Moderately Active Rheumatoid Arthritis Despite DMARD Therapy
Brief Summary: This study is designed to evaluate the effectiveness of adding etanercept to disease modifying anti-rheumatic drug (DMARD) therapy in patients with moderately active Rheumatoid Arthritis (RA).


Options:
A: Arm Label: 1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1a, 1b, 2a | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1a, 1b, 2a, 2b | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1b, 2a
B: Arm Label: Etanercept + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Biological: Etanercept, Drug: Methotrexate | Arm Label: Etanercept Only; Type: EXPERIMENTAL; Interventions: Biological: Etanercept, Drug: Methotrexate | Intervention Type: BIOLOGICAL; Name: Etanercept; Assigned to Arm(s): Etanercept + Methotrexate, Etanercept Only | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Etanercept + Methotrexate, Etanercept Only
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: etanercept, Drug: Placebo, Drug: DMARD Therapy | Arm Label: Etanercept; Type: EXPERIMENTAL; Interventions: Drug: etanercept, Drug: DMARD Therapy | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): Etanercept, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: DMARD Therapy; Assigned to Arm(s): Etanercept, Placebo
D: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Methotrexate placebo | Arm Label: Adalimumab + methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Methotrexate | Arm Label: Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Biological: Adalimumab placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Adalimumab + methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Adalimumab + methotrexate, Methotrexate | Intervention Type: BIOLOGICAL; Name: Adalimumab placebo; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Methotrexate placebo; Assigned to Arm(s): Adalimumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 6-month, Double-blind, Randomised, Multicenter, Multinational Trial to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Pulmonary Function in Patients With COPD. The ACROSS Trial
Brief Summary: The aim of this trial is to determine the efficacy, safety and tolerability of 500 µg Roflumilast tablets once daily in patients with COPD in China, Hong Kong, and Singapore.


Options:
A: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: UK-500,001; Assigned to Arm(s): N/A
D: Arm Label: Roflumilast; Type: EXPERIMENTAL; Interventions: Drug: Roflumilast, Drug: Salbutamol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Salbutamol | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Salbutamol; Assigned to Arm(s): Placebo, Roflumilast

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 6-month, Double-blind, Randomised, Multicenter, Multinational Trial to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Pulmonary Function in Patients With COPD. The ACROSS Trial
Brief Summary: The aim of this trial is to determine the efficacy, safety and tolerability of 500 µg Roflumilast tablets once daily in patients with COPD in China, Hong Kong, and Singapore.


Options:
A: Arm Label: Roflumilast; Type: EXPERIMENTAL; Interventions: Drug: Roflumilast, Drug: Salbutamol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Salbutamol | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Salbutamol; Assigned to Arm(s): Placebo, Roflumilast
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Roflumilast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): N/A
D: Arm Label: 25 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK256066 | Arm Label: 87.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK256066 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GSK256066; Assigned to Arm(s): 25 mcg, 87.5 mcg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial to Study the Effects of Infliximab on Clinical Efficacy and Hand and Wrist Magnetic Resonance Imaging (MRI) in Patients With Active Rheumatoid Arthritis (RA)(Protocol No. P08136)
Brief Summary: This is a study to compare the effect of infliximab versus placebo on synovial inflammation as measured by dynamic contrast enhanced (DCE)-MRI of one wrist. The primary hypothesis is that over 14 weeks of therapy, the change from baseline in the volume transfer rate in enhancing synovium is larger due to treatment with infliximab than with placebo.


Options:
A: Arm Label: ETN Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: ETN Alone | Arm Label: ETN+MTX; Type: ACTIVE_COMPARATOR; Interventions: Drug: ETN+MTX | Intervention Type: DRUG; Name: ETN Alone; Assigned to Arm(s): ETN Alone | Intervention Type: DRUG; Name: ETN+MTX; Assigned to Arm(s): ETN+MTX
B: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Methotrexate placebo | Arm Label: Adalimumab + methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Methotrexate | Arm Label: Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Biological: Adalimumab placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Adalimumab + methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Adalimumab + methotrexate, Methotrexate | Intervention Type: BIOLOGICAL; Name: Adalimumab placebo; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Methotrexate placebo; Assigned to Arm(s): Adalimumab
C: Arm Label: Infliximab; Type: EXPERIMENTAL; Interventions: Drug: Infliximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Infliximab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept , Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide | Intervention Type: DRUG; Name: Etanercept , Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial to Study the Effects of Infliximab on Clinical Efficacy and Hand and Wrist Magnetic Resonance Imaging (MRI) in Patients With Active Rheumatoid Arthritis (RA)(Protocol No. P08136)
Brief Summary: This is a study to compare the effect of infliximab versus placebo on synovial inflammation as measured by dynamic contrast enhanced (DCE)-MRI of one wrist. The primary hypothesis is that over 14 weeks of therapy, the change from baseline in the volume transfer rate in enhancing synovium is larger due to treatment with infliximab than with placebo.


Options:
A: Arm Label: Abatacept, 125 mg, plus methotrexate, 2.5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept, Drug: Methotrexate | Arm Label: Methotrexate, 2.5 mg, plus abatacept placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Abatacept placebo | Arm Label: Abatacept, 125 mg, plus methotrexate placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept, Drug: Methotrexate placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept, 125 mg, plus methotrexate placebo, Abatacept, 125 mg, plus methotrexate, 2.5 mg | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Abatacept, 125 mg, plus methotrexate, 2.5 mg, Methotrexate, 2.5 mg, plus abatacept placebo | Intervention Type: DRUG; Name: Abatacept placebo; Assigned to Arm(s): Methotrexate, 2.5 mg, plus abatacept placebo | Intervention Type: DRUG; Name: Methotrexate placebo; Assigned to Arm(s): Abatacept, 125 mg, plus methotrexate placebo
B: Arm Label: Infliximab; Type: EXPERIMENTAL; Interventions: Drug: Infliximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Infliximab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Certolizumab pegol (CDP870); Assigned to Arm(s): N/A
D: Arm Label: Open Label Infliximab + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Infliximab + methotrexate (MTX) | Intervention Type: BIOLOGICAL; Name: Infliximab + methotrexate (MTX); Assigned to Arm(s): Open Label Infliximab + Methotrexate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial to Study the Effects of Infliximab on Clinical Efficacy and Hand and Wrist Magnetic Resonance Imaging (MRI) in Patients With Active Rheumatoid Arthritis (RA)(Protocol No. P08136)
Brief Summary: This is a study to compare the effect of infliximab versus placebo on synovial inflammation as measured by dynamic contrast enhanced (DCE)-MRI of one wrist. The primary hypothesis is that over 14 weeks of therapy, the change from baseline in the volume transfer rate in enhancing synovium is larger due to treatment with infliximab than with placebo.


Options:
A: Arm Label: ADA+MTX/PBO+MTX (Arm 1); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate, Biological: placebo | Arm Label: ADA+MTX/ADA+MTX (Arm2); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate | Arm Label: ADA+MTX/OL ADA+MTX (Arm 3); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate | Arm Label: PBO+MTX/PBO+MTX (Arm 4); Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Biological: placebo | Arm Label: PBO+MTX/OL ADA+MTX (Arm 5); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate, Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): ADA+MTX/ADA+MTX (Arm2), ADA+MTX/OL ADA+MTX (Arm 3), ADA+MTX/PBO+MTX (Arm 1), PBO+MTX/OL ADA+MTX (Arm 5) | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): ADA+MTX/ADA+MTX (Arm2), ADA+MTX/OL ADA+MTX (Arm 3), ADA+MTX/PBO+MTX (Arm 1), PBO+MTX/OL ADA+MTX (Arm 5), PBO+MTX/PBO+MTX (Arm 4) | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): ADA+MTX/PBO+MTX (Arm 1), PBO+MTX/OL ADA+MTX (Arm 5), PBO+MTX/PBO+MTX (Arm 4)
B: Arm Label: Infliximab; Type: EXPERIMENTAL; Interventions: Drug: Infliximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Infliximab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Certolizumab pegol (CZP); Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol (CZP) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol (CZP); Assigned to Arm(s): Certolizumab pegol (CZP) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Open-Label Active Treatment Enrolled from Phase 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Open-Label Active Treatment Enrolled from Phase 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Open-Label Active Treatment Enrolled from Phase 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Open-Label Active Treatment Enrolled from Phase 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection
Brief Summary: The AIR-BX1 study enrolled people with non-cystic fibrosis (non-CF) bronchiectasis and gram-negative airway infection. Participants received two 28-day courses of either Aztreonam for Inhalation Solution (AZLI) or placebo taken 3 times a day. Each course was followed by a 28-day off-drug period. Following the two blinded courses, all participants received a 28-day course of open-label AZLI then were followed for an additional 56 days.


Options:
A: Arm Label: Ciprofloxacin Inhale (BAYQ3939); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (Cipro, BAYQ3939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (Cipro, BAYQ3939); Assigned to Arm(s): Ciprofloxacin Inhale (BAYQ3939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin DPI (BAYQ3939); Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14), Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14), Placebo 28 Days on/off (Placebo 28)
C: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI
D: Arm Label: Azithromycin treatment 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin treatment 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo 2

Answer: C